Hepatology Communications最新文献_第2页

Baveno VII for HCC: Are we there yet? HCC 的 Baveno VII：我们到了吗？

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-30 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000542

Ashraf Ullah, Umar I J Choudhary, Naeem A Khan, Syed B Shah

引用次数: 0

Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis. 未列入肝移植名单的急性肝衰竭患者的预后：队列分析

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-30 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000575

Victor Dong, Valerie Durkalski, William M Lee, Constantine J Karvellas

{"title":"Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis.","authors":"Victor Dong, Valerie Durkalski, William M Lee, Constantine J Karvellas","doi":"10.1097/HC9.0000000000000575","DOIUrl":"10.1097/HC9.0000000000000575","url":null,"abstract":"Background: Acute liver failure (ALF) is a rare condition leading to morbidity and mortality. Liver transplantation (LT) is often required, but patients are not always listed for LT. There is a lack of data regarding outcomes in these patients. Our aim is to describe outcomes of patients with ALF not listed for LT and to compare this with those listed for LT.Methods: Retrospective analysis of all nonlisted patients with ALF enrolled in the Acute Liver Failure Study Group (ALFSG) registry between 1998 and 2018. The primary outcome was 21-day mortality. Multivariable logistic regression was done to identify factors associated with 21-day mortality. The comparison was then made with patients with ALF listed for LT.Results: A total of 1672 patients with ALF were not listed for LT. The median age was 41 (IQR: 30-54). Three hundred seventy-one (28.9%) patients were too sick to list. The most common etiology was acetaminophen toxicity (54.8%). Five hundred fifty-eight (35.7%) patients died at 21 days. After adjusting for relevant covariates, King's College Criteria (adjusted odds ratio: 3.17, CI 2.23-4.51), mechanical ventilation (adjusted odds ratio: 1.53, CI: 1.01-2.33), and vasopressors (adjusted odds ratio: 2.10, CI: 1.43-3.08) (p < 0.05 for all) were independently associated with 21-day mortality. Compared to listed patients, nonlisted patients had higher mortality (35.7% vs. 24.3%). Patients deemed not sick enough had greater than 95% survival, while those deemed too sick still had >30% survival.Conclusions: Despite no LT, the majority of patients were alive at 21 days. Survival was lower in nonlisted patients. Clinicians are more accurate in deeming patients not sick enough to require LT as opposed to deeming patients too sick to survive.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply: Statins for the prevention of cirrhosis complications: An American emulation of the StatLiver trial. 回复：预防肝硬化并发症的他汀类药物：美国效仿 StatLiver 试验。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-30 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000551

Nina Kimer, Thit M Kronborg, Flemming Bendtsen

引用次数: 0

The influence of biophysical niche on tumor-associated macrophages in liver cancer. 生物物理生态位对肝癌中肿瘤相关巨噬细胞的影响

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-30 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000569

Ying Zhang, Ying Rao, Jiahuan Lu, Jiyu Wang, Dai Fei Elmer Ker, Jingying Zhou, Dan Michelle Wang

{"title":"The influence of biophysical niche on tumor-associated macrophages in liver cancer.","authors":"Ying Zhang, Ying Rao, Jiahuan Lu, Jiyu Wang, Dai Fei Elmer Ker, Jingying Zhou, Dan Michelle Wang","doi":"10.1097/HC9.0000000000000569","DOIUrl":"10.1097/HC9.0000000000000569","url":null,"abstract":"HCC, the most common type of primary liver cancer, is a leading cause of cancer-related mortality worldwide. Although the advancement of immunotherapies by immune checkpoint inhibitors (ICIs) that target programmed cell death 1 or programmed cell death 1-ligand 1 has revolutionized the treatment for HCC, the majority is still not beneficial. Accumulating evidence has pointed out that the potent immunosuppressive tumor microenvironment in HCC poses a great challenge to ICI therapeutic efficacy. As a key component in tumor microenvironment, tumor-associated macrophages (TAMs) play vital roles in HCC development, progression, and ICI low responsiveness. Mechanistically, TAM can promote cancer invasion and metastasis, angiogenesis, epithelial-mesenchymal transition, maintenance of stemness, and most importantly, immunosuppression. Targeting TAMs, therefore, represents an opportunity to enhance the ICI therapeutic efficacy in patients with HCC. While previous research has primarily focused on biochemical cues influencing macrophages, emerging evidence highlights the critical role of biophysical signals, such as substrate stiffness, topography, and external forces. In this review, we summarize the influence of biophysical characteristics within the tumor microenvironment that regulate the phenotype and function of TAMs in HCC pathogenesis and progression. We also explore the possible mechanisms and discuss the potential of manipulating biophysical cues in regulating TAM for HCC therapy. By gaining a deeper understanding of how macrophages sense and respond to mechanical forces, we may potentially usher in a path toward a curative approach for combinatory cancer immunotherapies.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus. 糖尿病和代谢功能障碍相关脂肪性肝病患者的临床护理指南：联合共识。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-30 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000571

Jee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, Feng-Chih Shen, Chi-Ming Tai, Jung-Fu Chen, Yi-Hsiang Huang, Chih-Yao Hsu, Pin-Nan Cheng, Ching-Ling Lin, Chao-Hung Hung, Ching-Chu Chen, Mei-Hsuan Lee, Chun-Chuan Lee, Chih-Wen Lin, Sung-Chen Liu, Hwai-I Yang, Rong-Nan Chien, Chin-Sung Kuo, Cheng-Yuan Peng, Ming-Ling Chang, Chung-Feng Huang, Yi-Sun Yang, Hung-Chih Yang, Han-Chieh Lin, Horng-Yih Ou, Chun-Jen Liu, Chin-Hsiao Tseng, Jia-Horng Kao, Wan-Long Chuang, Chien-Ning Huang, Pei-Jer Chen, Chih-Yuan Wang, Ming-Lung Yu

{"title":"Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus.","authors":"Jee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, Feng-Chih Shen, Chi-Ming Tai, Jung-Fu Chen, Yi-Hsiang Huang, Chih-Yao Hsu, Pin-Nan Cheng, Ching-Ling Lin, Chao-Hung Hung, Ching-Chu Chen, Mei-Hsuan Lee, Chun-Chuan Lee, Chih-Wen Lin, Sung-Chen Liu, Hwai-I Yang, Rong-Nan Chien, Chin-Sung Kuo, Cheng-Yuan Peng, Ming-Ling Chang, Chung-Feng Huang, Yi-Sun Yang, Hung-Chih Yang, Han-Chieh Lin, Horng-Yih Ou, Chun-Jen Liu, Chin-Hsiao Tseng, Jia-Horng Kao, Wan-Long Chuang, Chien-Ning Huang, Pei-Jer Chen, Chih-Yuan Wang, Ming-Lung Yu","doi":"10.1097/HC9.0000000000000571","DOIUrl":"10.1097/HC9.0000000000000571","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting >30% of the global population. Metabolic dysregulation, particularly insulin resistance and its subsequent manifestation as type 2 diabetes mellitus, serves as the fundamental pathogenesis of metabolic liver disease. Clinical evidence of the recent nomenclature evolution is accumulating. The interaction and impacts are bidirectional between MASLD and diabetes in terms of disease course, risk, and prognosis. Therefore, there is an urgent need to highlight the multifaceted links between MASLD and diabetes for both hepatologists and diabetologists. The surveillance strategy, risk stratification of management, and current therapeutic achievements of metabolic liver disease remain the major pillars in a clinical care setting. Therefore, the Taiwan Association for the Study of the Liver (TASL), Taiwanese Association of Diabetes Educators, and Diabetes Association of the Republic of China (Taiwan) collaboratively completed the first guidance in patients with diabetes and MASLD, which provides practical recommendations for patient care.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patient-centered approach to dietary supplements for patients with chronic liver disease. 以患者为中心的慢性肝病患者膳食补充剂方法。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-24 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000552

Jennifer C Lai, Melinda Ring, Anand Dhruva, Gloria Y Yeh

{"title":"A patient-centered approach to dietary supplements for patients with chronic liver disease.","authors":"Jennifer C Lai, Melinda Ring, Anand Dhruva, Gloria Y Yeh","doi":"10.1097/HC9.0000000000000552","DOIUrl":"10.1097/HC9.0000000000000552","url":null,"abstract":"The use of dietary supplements by patients with chronic liver disease is prevalent and rising. Despite the known risks of dietary supplements, including hepatotoxicity, adulteration, and contamination, patients with chronic liver disease often turn to dietary supplements to support their liver and/or overall health but are not necessarily empowered with the information or guidance from their liver practitioner to do so. This article provides practitioners with a framework for balancing the risks and benefits of dietary supplements in patients with chronic liver disease, offering examples of independent resources and certifications to use this framework in clinical practice. We offer 3 common clinical scenarios to highlight how the use of this framework can improve communication and decision-making in clinical practice. By adapting principles from Integrative Medicine, this article advocates for a patient-centered approach to dietary supplements in patients with chronic liver disease, encouraging open dialogue between clinicians and their patients to facilitate informed decision-making and personalized care.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142499331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial. 补锌改善代偿期晚期慢性肝病患者的预后：一项多中心、随机、双盲、安慰剂对照临床试验。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-10 eCollection Date: 2024-11-01 DOI: 10.1097/HC9.0000000000000524

Juan Bañares, Laia Aceituno, Lourdes Ruiz-Ortega, Mònica Pons, Juan G Abraldes, Joan Genescà

{"title":"Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial.","authors":"Juan Bañares, Laia Aceituno, Lourdes Ruiz-Ortega, Mònica Pons, Juan G Abraldes, Joan Genescà","doi":"10.1097/HC9.0000000000000524","DOIUrl":"10.1097/HC9.0000000000000524","url":null,"abstract":"Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous group of patients with variable risks of clinically significant portal hypertension and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that zinc administration can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death, and liver transplantation). This study protocol describes an ongoing phase III, national, multicenter, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimum follow-up of 2 years. Our principal hypothesis is that zinc could modify the natural history of patients with compensated advanced chronic liver disease, with an overall improvement in prognosis.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda. 肝硬化失代偿期的感染：病理生理学、管理和研究议程。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-03 eCollection Date: 2024-10-01 DOI: 10.1097/HC9.0000000000000539

Jessica Ferguson Toll, Elsa Solà, Maria Alejandra Perez, Salvatore Piano, Alice Cheng, Aruna K Subramanian, W Ray Kim

引用次数: 0

A need for confirmatory testing of isolated HBcAb-positive results in screening programs. 在筛查项目中，需要对分离出的 HBcAb 阳性结果进行确证检测。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-03 eCollection Date: 2024-10-01 DOI: 10.1097/HC9.0000000000000554

Michael X Fu, Peter Simmonds, Heli Harvala

引用次数: 0

Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE. 微环境中相互作用的增强加速了 TACE 后 HBV 相关 HCC 的不良预后。

IF 5.6 2区医学

Hepatology Communications Pub Date : 2024-10-03 eCollection Date: 2024-10-01 DOI: 10.1097/HC9.0000000000000548

Libo Wang, Jiahui Cao, Zaoqu Liu, Shitao Wu, Yin Liu, Ruopeng Liang, Rongtao Zhu, Weijie Wang, Jian Li, Yuling Sun

{"title":"Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE.","authors":"Libo Wang, Jiahui Cao, Zaoqu Liu, Shitao Wu, Yin Liu, Ruopeng Liang, Rongtao Zhu, Weijie Wang, Jian Li, Yuling Sun","doi":"10.1097/HC9.0000000000000548","DOIUrl":"10.1097/HC9.0000000000000548","url":null,"abstract":"Background: Transarterial chemoembolization (TACE) is the first-line treatment for patients with advanced HCC, but there are limited studies on the microenvironment alterations caused by TACE.Methods: Six fresh HBV-related HCC specimens with or without TACE intervention were used to perform single-cell RNA sequencing. The 757 bulk samples from 3 large-scale multicenter cohorts were applied for comprehensive analysis. The biological functions of the biomarkers were further validated by phenotypic experiments.Results: Using single-cell RNA sequencing analysis, we delineated the global cell atlas of post-TACE and demonstrated elevated tumor heterogeneity and an enhanced proinflammatory microenvironment induced by TACE. Cell-cell communication analysis revealed that markedly elevated interactions between NABP1+ malignant hepatocytes, neutrophils, and CD8+ T cells after TACE might accelerate the shift from CD8+ effector memory T cells to CD8+ effector T cells. This result was substantiated by the developmental trajectory between the 2 and dramatically decreased resident scores along the pseudotemporal trajectory. Integrating bulk data, we further found that the increased estimated proportion of NABP1+ malignant hepatocytes was related to poor TACE response and dismal prognosis, and its biomarker role could be replaced by NABP1. In vitro, multiple biological experiments consistently verified that NABP1 knockdown significantly inhibited the proliferation and migration of HCC cells.Conclusions: Based on our depicted global map of post-TACE, we confirmed that the enhanced interactions within the microenvironment after TACE may be the culprits for postoperative progression. NABP1 may become an attractive tool for the early identification of patients sensitive to first-line TACE in clinical practice.","PeriodicalId":12978,"journal":{"name":"Hepatology Communications","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0